The top 5 peptides for weight loss in 2026

In just a few years, peptides have moved from a niche corner of the supplement world to one of the most discussed categories in modern medicine. Behind that shift sits a single class of compounds: GLP-1 receptor agonists. From Ozempic to Mounjaro and the next generation of triple agonists like Retatrutide, GLP-1 chemistry has redefined what's possible in weight management.

But "peptides for weight loss" isn't a single thing. The top five compounds most discussed in 2026 each take a slightly different approach to the same problem — making your appetite, satiety, gastric emptying, insulin response, and metabolic rate work for you instead of against you. Some are FDA-approved blockbusters. Others are still in late-stage trials. A few are designed to be combined with each other, not used alone.

This guide walks through the five most-studied weight-loss peptides of 2026 — what they do, how they work, and where each one fits in the broader landscape. We'll cover their mechanisms, typical dosing ranges, side-effect profiles, and trial outcomes so you can build a clear mental model of how this category is evolving.

A note before we begin: nothing in this article constitutes medical advice. Many of these compounds are prescription-only or still investigational. Anyone considering peptide therapy should work with a qualified healthcare professional.

1. Tirzepatide — the current king

If you ask any clinician or peptide researcher to name the most important compound in weight loss right now, you'll get the same answer: Tirzepatide.

Sold under the brand names Mounjaro and Zepbound, Tirzepatide was the first peptide to combine two metabolic mechanisms in a single molecule — GLP-1 and GIP receptor agonism. That dual mechanism turns out to be more than the sum of its parts. In phase 3 trials, participants on the highest dose lost approximately 22% of their body weight at 72 weeks — numbers that previously only appeared in bariatric surgery outcomes.

How it works

Tirzepatide binds both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The GLP-1 arm reduces appetite, slows gastric emptying, and improves the body's insulin response to meals. The GIP arm amplifies insulin secretion further and may improve how fat tissue handles excess energy. Together, the two receptors push weight loss further than either could alone.

Dosing & side effects

Once-weekly subcutaneous injection, typically titrated upward over months from 2.5 mg to 15 mg as tolerated. Slow titration is critical to manage gastrointestinal side effects — primarily nausea (especially during dose increases), constipation or diarrhea, decreased appetite, and occasional injection-site reactions. Most resolve as the body adjusts.

Why it matters

Tirzepatide is the first compound to make GLP-1 weight loss feel almost mainstream. Its outcomes are strong enough that it's now reshaping how clinicians think about obesity as a treatable, chronic condition rather than a behavioral failure.

2. Semaglutide — the original blockbuster

Before Tirzepatide there was Semaglutide — the compound that turned "Ozempic" into a household word and changed how the public talks about obesity.

Sold as Ozempic (for diabetes) and Wegovy (for weight management), Semaglutide is a long-acting GLP-1 receptor agonist. It set the bar that every newer peptide is now measured against. In the STEP clinical trial program, weekly Semaglutide produced approximately 15% body-weight reduction at 68 weeks — a result that, before Tirzepatide arrived, seemed almost impossible for a non-surgical intervention.

How it works

Semaglutide binds GLP-1 receptors throughout the body, with key activity in the pancreas, hypothalamus, and gastrointestinal tract. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric motility, and signals satiety in appetite-regulating brain regions.

Dosing & side effects

Once-weekly subcutaneous injection at 0.25–2.4 mg per week, with slow titration to mitigate GI side effects. The most common are nausea (especially early), constipation, diarrhea, and fatigue — plus rarer reports of pancreatitis or gallbladder issues that are worth discussing with a clinician before starting.

Why it matters

Even now, with Tirzepatide outperforming it on raw weight-loss numbers, Semaglutide remains the most prescribed GLP-1 in the world — partly because of brand recognition, partly because its slightly milder side-effect profile suits some patients better, and partly because of its now-expanding cardiovascular protection data.

3. Retatrutide — the triple agonist

If Tirzepatide is the king and Semaglutide is the elder statesman, Retatrutide is the heir apparent.

Often described as the "future Ozempic," Retatrutide is the first peptide to simultaneously activate three metabolic receptors — GLP-1, GIP, and glucagon. That triple action has produced the largest weight-loss percentages ever recorded in trials. In phase 2 results from Eli Lilly's TRIUMPH program, participants on the highest dose averaged over 24% body-weight reduction at 48 weeks, with a notable subset crossing 30%.

How it works

Retatrutide adds a glucagon receptor arm to the dual mechanism of Tirzepatide. While GLP-1 and GIP suppress appetite and improve insulin response, the glucagon arm increases lipolysis (fat breakdown) and total energy expenditure. The combination essentially pushes the body to spend more calories while also eating fewer.

Dosing & side effects

Currently investigational, with weekly subcutaneous trial doses ranging from 1 mg to 12 mg. Like other incretin therapies, slow titration is essential. Expect a side-effect profile comparable to other GLP-1s — nausea, vomiting, constipation, decreased appetite — with the added consideration of possible heart-rate elevation from glucagon receptor activation.

Why it matters

Retatrutide isn't approved yet, but it's the strongest signal in the room that GLP-1 chemistry hasn't peaked. Each generation adds a receptor and pushes outcomes further.

4. Cagrilintide — the combination play

The fourth peptide on this list works differently from the first three — and that's exactly the point.

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk to be combined with Semaglutide in a single product called CagriSema. Amylin is a natural hormone that signals satiety and slows gastric emptying through pathways completely separate from GLP-1, which means stacking the two creates additive effects without overlapping side-effect profiles.

How it works

Cagrilintide activates amylin and calcitonin receptors, suppressing appetite and slowing digestion through a different signaling cascade than GLP-1. When combined with Semaglutide, you get simultaneous activation of both pathways — meaning the brain receives stronger and more persistent satiety signals than either compound provides alone.

Dosing & side effects

Currently investigational, with weekly subcutaneous trial doses ranging from 0.16 mg to 2.4 mg, typically alongside Semaglutide. Side effects mirror GLP-1 therapy — nausea, vomiting, decreased appetite — though they tend to be more manageable when titrated alongside Semaglutide rather than as a standalone agent.

Why it matters

Cagrilintide represents a different strategy: not finding a stronger single molecule, but stacking complementary mechanisms. That logic is likely to define the next decade of obesity therapy.

5. Orforglipron — the oral frontier

Every peptide on this list so far is injectable. Orforglipron changes that.

Developed by Eli Lilly, Orforglipron is a small-molecule GLP-1 receptor agonist taken as a daily oral tablet. It isn't technically a peptide — it's a non-peptide ligand designed to engage the same GLP-1 receptor — but it's almost universally discussed alongside the GLP-1 peptide class because it represents the same therapeutic future delivered in a different form.

How it works

Orforglipron binds and activates the GLP-1 receptor, triggering the same downstream cascade as injectable GLP-1s — enhanced glucose-dependent insulin secretion, suppressed glucagon, slower gastric emptying, and central satiety signals. The difference is purely in delivery: a once-daily pill instead of a weekly injection.

Dosing & side effects

Currently investigational, with daily oral doses studied across a 3 mg to 45 mg range. Unlike older oral GLP-1s, it doesn't require fasting windows or specific water restrictions. Side-effect profile largely mirrors injectable GLP-1s: nausea, vomiting, diarrhea, decreased appetite, occasional heart-rate elevation.

Why it matters

Once Orforglipron and similar oral agents are approved, the bottleneck for GLP-1 access changes from injection logistics and cold-chain storage to simply prescribing a daily pill. That alone could double or triple the addressable market.

How to think about this category

If you've read this far, you've probably noticed a pattern: every compound here works on appetite, satiety, and metabolic signaling — but each takes a different angle.

• Tirzepatide and Semaglutide are the proven, FDA-approved options with the most clinical and real-world data.
• Retatrutide is the cutting edge — stronger results, but not yet approved.
• Cagrilintide is the combination play — designed to amplify Semaglutide's effects rather than replace them.
• Orforglipron changes the delivery method entirely, potentially opening GLP-1 therapy to a much wider audience.

For anyone trying to make sense of the space, the biggest insight is that "weight-loss peptides" is not a static category. Every 12 to 18 months a new compound, mechanism, or delivery method moves the field forward. What was state-of-the-art two years ago (Semaglutide) is no longer the best single option (now Tirzepatide), which itself may be displaced within a year or two (by Retatrutide).

That pace makes ongoing education essential. PeptidesForX maintains profiles for each of these compounds — including full mechanism breakdowns, dosing references, and side-effect profiles — that we update as new trial data emerges.

A word on safety

Every compound on this list affects appetite, blood sugar, gastrointestinal function, and metabolic signaling — sometimes profoundly. A few key reminders:

• Most of these are prescription-only. Tirzepatide, Semaglutide, and clinical formulations of others are tightly regulated.
• Several are still investigational. Retatrutide, Cagrilintide, and Orforglipron are not yet approved for general use.
• Side effects are real. GI symptoms can be significant, especially during dose titration. Long-term safety profiles are still being characterized.
• Medical supervision is essential. Anyone considering any peptide therapy should work with a qualified physician familiar with the compound — not solely rely on online communities.

PeptidesForX is an educational resource. Nothing on this site constitutes medical advice. Please consult a licensed healthcare professional before making any decision about peptide use.

Tools to pair with this guide

If you're researching dosing scenarios for any of these peptides, two of our calculators are particularly useful:

• Dosage Calculator — converts a target dose rate (mcg/kg) into a per-dose recommendation based on body weight.
• Reconstitution Calculator — translates vial size and bacteriostatic water volume into mcg per insulin syringe unit.

For the full directory of all 34 peptides covered on this site — including the GLP-1 family above plus recovery, growth-hormone, longevity, and cognitive compounds — visit the Peptides directory or browse the Weight Loss category page.